Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus

Journal of Infectious Diseases

Volumn 214, Issue 3, 2016, Pages 369-378

  Muthumani, Karuppiah ^a,b   Block, Peter ^a   Flingai, Seleeke ^a,b   Muruganantham, Nagarajan ^c   Chaaithanya, Itta Krishna ^c   Tingey, Colleen ^a   Wise, Megan ^a,b   Reuschel, Emma L ^a,b   Chung, Christopher ^a,b   Muthumani, Abirami ^a   Sarangan, Gopalsamy ^d   Srikanth, Padma ^d   Khan, Amir S ^e   Vijayachari, Paluru ^c   Sardesai, Niranjan Y ^e   Kim, J Joseph ^e   Ugen, Kenneth E ^f   Weiner, David B ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

^c INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^d SRI RAMACHANDRA UNIVERSITY   (India)

^e Inovio Pharmaceuticals   (United States)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

chikungunya virus; dMAb; DNA plasmid; monoclonal antibody; passive antibody prophylaxis and therapy

Indexed keywords

CHIKUNGUNYA VIRUS ENVELOPE MONOCLONAL ANTIBODY; DNA VACCINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL EXPERIMENT; ARTICLE; BINDING ASSAY; CHIKUNGUNYA; CHIKUNGUNYA VIRUS; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG EFFICACY; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNITY; IMMUNOFLUORESCENCE; IMMUNOTHERAPY; IN VIVO STUDY; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CHEMOPROPHYLAXIS; CHIKUNGUNYA FEVER; DISEASE MODEL; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; PROCEDURES; TIME FACTOR; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, VIRAL; CHEMOPREVENTION; CHIKUNGUNYA FEVER; DISEASE MODELS, ANIMAL; ELECTROPORATION; INJECTIONS, INTRAMUSCULAR; MICE, INBRED BALB C; TIME FACTORS; TREATMENT OUTCOME; VACCINES, DNA; VIRAL VACCINES;

EID: 84981173476     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw111     Document Type: Article

References (49)

1. Burt FJ, Rolph MS, Rulli NE, Mahalingam S, Heise MT. Chikungunya: a re-emerging virus. Lancet 2012; 379:662-71.
2. Akahata W, Yang ZY, Andersen H, et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med 2010; 16:334-8.
3. Coffey LL, Failloux AB, Weaver SC. Chikungunya virus-vector interactions. Viruses 2014; 6:4628-63.
4. Charrel RN, de Lamballerie X, Raoult D. Chikungunya outbreaks-the globalization of vectorborne diseases. N Engl J Med 2007; 356:769-71.
5. Teo TH, Lum FM, Claser C, et al. A pathogenic role for CD4+ T cells during Chikungunya virus infection in mice. J Immunol 2013; 190:259-69.
6. Teng TS, Foo SS, Simamarta D, et al. Viperin restricts chikungunya virus replication and pathology. J Clin Invest 2012; 122:4447-60.
7. Weaver SC, Osorio JE, Livengood JA, Chen R, Stinchcomb DT. Chikungunya virus and prospects for a vaccine. Expert Rev Vaccines 2012; 11:1087-101.
8. Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, Mangiafico JA. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg 2000; 62:681-5.
9. Kumar A, Mamidi P, Das I, et al. A novel 2006 Indian outbreak strain of Chikun-gunya virus exhibits different pattern of infection as compared to prototype strain. PLoS One 2014; 9:e85714.
10. Wang E, Volkova E, Adams AP, et al. Chimeric alphavirus vaccine candidates for chikungunya. Vaccine 2008; 26:5030-9.
11. Muthumani K, Lankaraman KM, Laddy DJ, et al. Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine 2008; 26:5128-34.
12. Mallilankaraman K, Shedlock DJ, Bao H, et al. A DNA vaccine against chikungu-nya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis 2011; 5:e928.
13. Garcia-Arriaza J, Cepeda V, Hallengard D, et al. A novel poxvirus-based vaccine (MVA-CHIKV) is highly immunogenic and protects mice against chikungunya infection. J Virol 2014; 88:3527-47.
14. Couderc T, Khandoudi N, Grandadam M, et al. Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis 2009; 200:516-23.
15. Fric J, Bertin-Maghit S, Wang CI, Nardin A, Warter L. Use of human monoclonal antibodies to treat Chikungunya virus infection. J Infect Dis 2013; 207:319-22.
16. Sheela PJ, Sumathy K. Serological correlates of immune protection conferred by Chikungunya virus infection. Acta Virol 2013; 57:471-3.
17. Manohar A, Ahuja J, Crane JK. Immunotherapy for Infectious Diseases: Past, Present, and Future. Immunol Invest 2015; 44:731-7.
18. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8:34-47.
19. Zheng K, Bantog C, Bayer R. The impact of glycosylation on monoclonal antibody conformation and stability. MAbs 2011; 3:568-76.
20. Zalevsky J, Chamberlain AK, Horton HM, et al. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 2010; 28:157-9.
21. Strop P, Ho WH, Boustany LM, et al. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J Mol Biol 2012; 420:204-19.
22. Barouch DH, Picker LJ. Novel vaccine vectors for HIV-1. Nat Rev Microbiol 2014; 12:765-71.
23. Warter L, Lee CY, Thiagarajan R, et al. Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency. J Immunol 2011; 186:3258-64.
24. Pal P, Dowd KA, Brien JD, et al. Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS Pathog 2013; 9: e1003312.
25. Flingai S, Plummer EM, Patel A, et al. Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy. Sci Rep 2015; 5:12616.
26. Johnson PR, Schnepp BC, Zhang J, et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 2009; 15:901-6.
27. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012; 481:81-4.
28. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12:342-7.
29. Ahi YS, Bangari DS, Mittal SK. Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther 2011; 11:307-20.
30. Wang L, Calcedo R, Bell P, et al. Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum Gene Ther 2011; 22:1389-401.
31. Muthumani K, Flingai S, Wise M, Tingey C, Ugen KE, Weiner DB. Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab. Hum Vaccin Immunother 2013; 9:2253-62.
32. Muthumani K, Falzarano D, Reuschel EL, et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med 2015; 7:301ra132.
33. Broderick KE, Khan AS, Sardesai NY. DNA vaccination in skin enhanced by electroporation. Methods Mol Biol 2014; 1143:123-30.
34. Muruganandam N, Chaaithanya IK, Senthil GS, et al. Isolation and molecular characterization of Chikungunya virus from the Andaman and Nicobar archipelago, India: evidence of an East, Central, and South African genotype. Can J Micro-biol 2011; 57:1073-7.
35. Muthumani K, Wise MC, Broderick KE, et al. HIV-1 Env DNA vaccine plus protein boost delivered by EP expands B-and T-cell responses and neutralizing phenotype in vivo. PLoS One 2013; 8:e84234.
36. Sun S, Xiang Y, Akahata W, et al. Structural analyses at pseudo atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization. eLife 2013; 2:e00435.
37. Ziegler SA, Lu L, da Rosa AP, Xiao SY, Tesh RB. An animal model for studying the pathogenesis of chikungunya virus infection. Am J Trop Med Hyg 2008; 79:133-9.
38. Hudson PJ, Souriau C. Engineered antibodies. Nat Med 2003; 9:129-34.
39. Smith SA, Silva LA, Fox JM, et al. Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus. Cell Host Microbe 2015; 18:86-95.
40. Couderc T, Chretien F, Schilte C, et al. A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog 2008; 4:e29.
41. Laddy DJ, Yan J, Kutzler M, et al. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS ONE 2008; 3:e2517.
42. Ng LF, Chow A, Sun YJ, et al. IL-1beta, IL-6, and RANTES as biomarkers of Chikungunya severity. PLoS ONE 2009; 4:e4261.
43. Chaaitanya IK, Muruganandam N, Sundaram SG, et al. Role of proinflammatory cytokines and chemokines in chronic arthropathy in CHIKV infection. Viral Immunol 2011; 24:265-71.
44. Krammer F, Palese P. Universal influenza virus vaccines: need for clinical trials. Nat Immunol 2014; 15:3-5.
45. Walker BD, Ahmed R, Plotkin S. Moving ahead an HIV vaccine: use both arms to beat HIV. Nat Med 2011; 17:1194-5.
46. Kalams SA, Parker S, Jin X, et al. Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. PLoS One 2012; 7:e29231.
47. Trimble CL, Morrow MP, Kraynyak KA, et al. Safety, efficacy, and immunogenic-ity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillo-mavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet 2015; 386:2078-88.
48. Lienert F, Lohmueller JJ, Garg A, Silver PA. Synthetic biology in mammalian cells: next generation research tools and therapeutics. Nat Rev Mol Cell Biol 2014; 15:95-107.
49. Hutnick NA, Myles DJ, Ferraro B, et al. Intradermal DNA vaccination enhanced by low-current electroporation improves antigen expression and induces robust cellular and humoral immune responses. Hum Gene Ther 2012; 23: 943-50.